Have you been diagnosed with Advanced Prostate Cancer? If so, you may be able to take part in an International Registry for Men.

Have you recently been diagnosed with breast cancer but have not yet started treatment (other than surgery)? You may be able to take part in the UNC CogMAP study. In this study, we want to learn more about cognitive and brain function before and after cancer treatment. This will help us to better understand risk factors for experiencing cognitive difficulties during and after treatment.

In this study, we want to interview women with pregnancy Medicaid in North Carolina. We would like to learn what would help more people go to the dentist and get dental care during this time. That way, we can make suggestions for policy changes to help more people get the care they need.

Metabolism is the process your body uses to make energy. The main purpose of this study is to observe the impact of metabolic processes on cognition and behavior.

Participants are asked to come into the lab for a 1.5-hour session. During this session they will complete questionnaires and tasks. Questionnaires will ask about physical and mental health, life experiences, emotions, and cognitive associations. Tasks are designed to measure participants' sensitivity to heartbeat and stomach sensations, as well as socioemotional functioning.

Fuel for Thought: How do sugar and fat affect each other in the brain? Do you ever wonder what happens in your brain when you eat dessert? And why sugary and fatty foods are so appealing? If so, you may eligible to participate in a research study to understand the impact of sugar and fat on the brain!

This study is assessing the effectiveness and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when given with atezolizumab and bevacizumab as a first-line treatment for unresectable, locally advanced or metastatic patients with hepatocellular carcinoma (HCC). TIGIT is thought to play an important role in HCC's response to immunotherapy treatments such as atezolizumab. This study will assess whether the addition of tiragolumab to atezolizumab and bevacizumab will improve response and clinical outcomes.

To evaluate the best overall response rate (BOR) of recurrent/metastatic androgen receptor positive (AR+) salivary gland cancer (SGC) patients with darolutamide and androgen deprivation therapy (ADT).

The purpose of this study is to test good and bad effects of different drugs against metastatic brain tumors with altered genes. This trial is trying to see if tumor genetic testing would be helpful at guiding treatment in patients such as you. Researchers have looked at the DNA material (genes) that can be affected in brain metastases and have found several genes that are altered, or mutated. There are medications that target these genes. We are doing this study because we want to find out if this approach is better or worse than the usual approach for your metastatic cancer. The usual approach is defined as care most people get for your metastatic cancer.

Are you a Hispanic or Latino adult? You may be able to take part in a study to help us learn about reactions to food labels.